SkyView Investment Advisors’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

SkyView Investment Advisors’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30,000	Closed	-$4K	–	338
2024 Q4	$4K	Hold	30,000	–	–	﹤0.01%	263
2024 Q3	$4K	Hold	30,000	–	–	﹤0.01%	270
2024 Q2	$4K	Hold	30,000	–	–	﹤0.01%	316
2024 Q1	$4K	Hold	30,000	–	–	﹤0.01%	302
2023 Q4	$5K	Buy	+30,000	New	+$4.85K	﹤0.01%	112

SkyView Investment Advisors's BLACR Position: Q1 2025 in Review

SkyView Investment Advisors sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 30,000 shares — an estimated $4K sold.

SkyView Investment Advisors first reported a position in BLACR in Q4 2023 and held it in 5 quarters. The position peaked at $5K in Q4 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

SkyView Investment Advisors reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
SkyView Investment Advisors sold 30,000 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $4K.
SkyView Investment Advisors first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q4 2023 and held it in 5 quarters.
SkyView Investment Advisors's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $5K in Q4 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on SkyView Investment Advisors's 13F filing for Q1 2025, filed 15 Aug 2025.